ArticleMedChemComm2019
Novel zafirlukast derivatives exhibit selective antibacterial activity against
Article in MedChemComm, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Development of Zafirlukast Analogues for Improved Antithrombotic Activity Through Thiol Isomerase Inhibition.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Antibacterial Activity of Banglene Extracted from Indonesian Ginger "Bangle" AgainstInternational journal of molecular sciences · 2025Article
- Zafirlukast induces DNA condensation and has bactericidal effect on replicatingAntimicrobial agents and chemotherapy · 2024Article
- The Link between Periodontal Disease and Asthma: How Do These Two Diseases Affect Each Other?Journal of clinical medicine · 2023Review
- Selective Inhibition of the Periodontal PathogenJournal of medicinal chemistry · 2022Article
- Review
- Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes.NPJ biofilms and microbiomes · 2021Article
- Quercetin inhibits virulence properties of Porphyromas gingivalis in periodontal disease.Scientific reports · 2020Article
- Second Generation of Zafirlukast Derivatives with Improved Activity against the Oral PathogenACS medicinal chemistry letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontal disease is an oral chronic immune-inflammatory disease highly prevalent worldwide that is initiated by specific oral bacterial species leading to local and systemic effects. The development of new preventive/therapeutic strategies to specifically target oral periodontopathogens without perturbing oral microbiome species normally colonizing the oral cavity is needed. The fast and affordable strategy of repositioning of already FDA-approved drugs can be an answer to the development of novel treatments against periodontal pathogens such as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.